Germline Signature Predicts Adverse Effects With Anti-PD1/PDL1 Checkpoint Therapy
February 9th 2022Applying these findings in practice could improve clinicians’ ability to offer truly personalized cancer therapy by enabling consideration of toxicity along with other data predicting patients’ responses.
Read More
Trametinib Presents Potential New Standard-of-Care for Low-Grade Serous Ovarian Carcinoma
February 7th 2022Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.
Read More